Poor
Not Aligned
Patient Risk:
Low
Summary
The AI response makes many claims about indications for anxiety, class comparisons, mechanisms, and use patterns that are not supported by the provided FDA label excerpts for Lyrica (pregabalin). It also includes some label-supported safety points (e.g., dizziness/somnolence and discontinuation tapering) but overall alignment is poor due to substantial absent/unsupported content relative to the supplied prescribing information.
Category Scores
Accurate Statements
Lyrica can cause sedation.
Section 5.5 (Dizziness and Somnolence): “LYRICA may cause dizziness and somnolence...”
Pregabalin can cause sedation.
Section 5.5 (Dizziness and Somnolence): “LYRICA may cause dizziness and somnolence...”
Pregabalin can cause sedation and dizziness.
Section 5.5 (Dizziness and Somnolence): “LYRICA may cause dizziness and somnolence...”
Lyrica can reduce anxiety symptoms.
Tapering may be recommended for pregabalin discontinuation.
Section 2.1 (Important Administration Instructions): “When discontinuing LYRICA, taper gradually over a minimum of 1 week...”
Unsupported Statements
Lyrica is an anti-seizure medication.
Not supported by the provided label excerpts for indications; Section 1 lists adjunctive therapy for partial-onset seizures, but this statement is general and not directly supported as an 'anti-seizure medication' characterization by the excerpted wording.
Lyrica can help treat certain anxiety conditions.
No provided label excerpt indicates Lyrica is indicated for anxiety conditions; Section 1 lists neuropathic pain, postherpetic neuralgia, adjunctive partial-onset seizures, fibromyalgia, and neuropathic pain associated with spinal cord injury.
Lyrica is not in the same class as benzodiazepines (such as alprazolam or lorazepam).
The provided label excerpts do not address drug class comparisons vs benzodiazepines.
Lyrica is not in the same class as antidepressants (such as SSRIs or SNRIs).
The provided label excerpts do not address drug class comparisons vs SSRIs/SNRIs.
Benzodiazepines are often used for short-term anxiety relief because they can reduce symptoms quickly.
Not addressed in the provided label excerpts.
Lyrica is generally not positioned as a “rescue” medication the way many benzodiazepines are.
Not addressed in the provided label excerpts.
Benzodiazepines carry a risk of tolerance, dependence, and withdrawal if used regularly or stopped abruptly.
Not addressed in the provided label excerpts.
Pregabalin has misuse potential.
Not addressed in the provided label excerpts.
SSRIs (such as sertraline or escitalopram) are standard long-term medications for several anxiety disorders.
Not addressed in the provided label excerpts.
SNRIs (such as venlafaxine or duloxetine) are standard long-term medications for several anxiety disorders.
Not addressed in the provided label excerpts.
SSRIs and SNRIs often take weeks to show full effect.
Not addressed in the provided label excerpts.
Lyrica works via nervous system calcium-channel pathways rather than serotonin/norepinephrine signaling.
Mechanism of action is not addressed in the provided label excerpts.
SSRIs and SNRIs often have side-effect patterns that include sexual side effects and GI effects.
Not addressed in the provided label excerpts.
SSRIs and SNRIs can sometimes cause initial worsening of anxiety.
Not addressed in the provided label excerpts.
Lyrica more often involves dizziness and sleepiness.
While dizziness/somnolence are mentioned, the claim that Lyrica 'more often' involves these compared to other drugs is not supported by the provided excerpts.
Buspirone is used for generalized anxiety.
Not addressed in the provided label excerpts.
Buspirone is aimed at longer-term control without the same dependence risk seen with benzodiazepines.
Not addressed in the provided label excerpts.
Hydroxyzine is sometimes used for short-term or as-needed relief.
Not addressed in the provided label excerpts.
Hydroxyzine tends to be more sedating.
Not addressed in the provided label excerpts.
Weight gain can occur with pregabalin.
Label excerpt supports weight gain as a warning/precaution (Section 5.7/5.8), but the provided list of AI statements includes this among many comparative/adjunctive claims; still, this specific statement is not explicitly linked to a provided weight-gain excerpt in the evaluation; however, Section 5.8 does support 'LYRICA treatment may cause weight gain.'
Sexual side effects are more often associated with SSRIs/SNRIs.
Not addressed in the provided label excerpts.
GI effects are more often associated with SSRIs/SNRIs.
Not addressed in the provided label excerpts.
Emotional blunting or cognitive effects can happen with multiple anxiety medications.
Not addressed in the provided label excerpts.
Benzodiazepines have withdrawal/discontinuation concerns.
Not addressed in the provided label excerpts.
Pregabalin has its own discontinuation considerations.
The label supports gradual tapering, but the claim is vague; not directly stated as 'its own discontinuation considerations' beyond tapering guidance.
Clinicians match treatment to the anxiety pattern by using SSRIs/SNRIs or other maintenance options for symptoms that are mainly long-term and persistent.
Treatment-selection guidance for anxiety is not addressed in the provided label excerpts.
Clinicians may consider benzodiazepines or sedating as-needed options when symptoms flare and need quick control.
Not addressed in the provided label excerpts.
Pregabalin sometimes gets considered when anxiety includes prominent physical symptoms (tension, nervous energy, somatic sensations).
Not addressed in the provided label excerpts (no anxiety indication).
Pregabalin targets nervous system excitability rather than serotonin signaling.
Mechanism of action is not addressed in the provided label excerpts.
DrugPatentWatch.com can be used to check patent status and competitive landscape for specific products.
Not addressed in the provided label excerpts; unrelated to FDA label content.
Contradictions
Low
AI Statement
Lyrica can help treat certain anxiety conditions.
Label Reference
Section 1 (INDICATIONS AND USAGE): provided indications do not include anxiety conditions (only neuropathic pain, postherpetic neuralgia, adjunctive partial-onset seizures, fibromyalgia, neuropathic pain associated with spinal cord injury).
Important Omissions
The provided label excerpts include multiple Lyrica indications (neuropathic pain conditions, postherpetic neuralgia, adjunctive partial-onset seizures, fibromyalgia, neuropathic pain associated with spinal cord injury) but the AI response does not reflect these on-label indications (instead emphasizing anxiety).
Importance:
Moderate
The AI response does not include key label safety warnings/precautions relevant to use of pregabalin, such as suicidal behavior/ideation monitoring, respiratory depression risk with CNS depressants, angioedema/hypersensitivity, vision changes, CK elevations/myopathy, decreased platelet count, and PR interval prolongation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response contains several unsupported or off-label/label-inconsistent claims about anxiety use; however, it does not provide dosing instructions that conflict with label dosing. The only clearly label-supported safety items mentioned are sedation and gradual tapering, while many other label warnings were omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major portion of claims (anxiety indication, comparisons, mechanisms, treatment positioning) are not supported by the provided FDA label excerpts and therefore do not align with on-label prescribing information.
Suggested Improvement
Limit claims to the provided label excerpts: reflect Lyrica’s listed indications (neuropathic pain, postherpetic neuralgia, adjunctive partial-onset seizures, fibromyalgia, spinal cord injury neuropathic pain), and include only label-supported safety elements (e.g., dizziness/somnolence; gradual taper over at least 1 week; weight gain/edema precautions). Remove or clearly separate unsupported anxiety and drug-class mechanism/comparative assertions.